IL187427A0 - Formulations for alteration of biophysical properties of mucosal lining - Google Patents

Formulations for alteration of biophysical properties of mucosal lining

Info

Publication number
IL187427A0
IL187427A0 IL187427A IL18742707A IL187427A0 IL 187427 A0 IL187427 A0 IL 187427A0 IL 187427 A IL187427 A IL 187427A IL 18742707 A IL18742707 A IL 18742707A IL 187427 A0 IL187427 A0 IL 187427A0
Authority
IL
Israel
Prior art keywords
alteration
formulations
biophysical properties
mucosal lining
mucosal
Prior art date
Application number
IL187427A
Other languages
English (en)
Original Assignee
Pulmatrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Inc filed Critical Pulmatrix Inc
Publication of IL187427A0 publication Critical patent/IL187427A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL187427A 2005-05-18 2007-11-15 Formulations for alteration of biophysical properties of mucosal lining IL187427A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68235605P 2005-05-18 2005-05-18
PCT/US2006/019443 WO2006125153A2 (en) 2005-05-18 2006-05-18 Formulations for alteration of biophysical properties of mucosal lining

Publications (1)

Publication Number Publication Date
IL187427A0 true IL187427A0 (en) 2011-08-01

Family

ID=37401509

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187427A IL187427A0 (en) 2005-05-18 2007-11-15 Formulations for alteration of biophysical properties of mucosal lining

Country Status (13)

Country Link
US (2) US20070053844A1 (OSRAM)
EP (3) EP2402001A1 (OSRAM)
JP (2) JP2008540680A (OSRAM)
KR (1) KR20080018872A (OSRAM)
CN (2) CN102327285A (OSRAM)
AU (1) AU2006247077A1 (OSRAM)
BR (1) BRPI0609924A2 (OSRAM)
CA (1) CA2608752A1 (OSRAM)
EA (1) EA016072B1 (OSRAM)
IL (1) IL187427A0 (OSRAM)
NO (1) NO20076086L (OSRAM)
NZ (2) NZ593475A (OSRAM)
WO (1) WO2006125153A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
ATE538774T1 (de) * 2009-03-26 2012-01-15 Pulmatrix Inc Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
CA2754684A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
EP3858440A3 (en) * 2015-11-18 2021-11-03 The Board of Trustees of the Leland Stanford Junior University B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components
EP3737364A1 (en) * 2018-01-11 2020-11-18 Emphysema Solutions BV Compositions and methods for the treatment of lung emphysema and other forms of copd
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
US12128067B2 (en) 2018-11-29 2024-10-29 Yildiz Teknik Universitesi Nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
US20220051592A1 (en) * 2020-08-17 2022-02-17 Massachusetts Institute Of Technology Respiratory system simulator systems and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3229179C2 (de) * 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5571535A (en) * 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5898037A (en) * 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5709202A (en) * 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE218132T1 (de) * 1994-10-14 2002-06-15 Yamanouchi Pharma Co Ltd Azol-derivate
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
EP1067839A1 (en) * 1998-04-08 2001-01-17 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
FR2780285B1 (fr) * 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
AU4979700A (en) * 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU772096B2 (en) * 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
JP3481205B2 (ja) * 2000-11-24 2003-12-22 松下電器産業株式会社 インバータ制御用半導体装置および制御方法
AU2002245181B2 (en) * 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
CA2483917C (en) * 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US7534781B2 (en) * 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
WO2005004852A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
US20070275091A1 (en) * 2004-03-30 2007-11-29 Malcolm King Compositions And Methods For Improved Mucus Function
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20070202051A1 (en) * 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods

Also Published As

Publication number Publication date
WO2006125153A3 (en) 2008-02-28
KR20080018872A (ko) 2008-02-28
JP2012176990A (ja) 2012-09-13
NO20076086L (no) 2008-02-14
AU2006247077A1 (en) 2006-11-23
WO2006125153A2 (en) 2006-11-23
EP2308469A1 (en) 2011-04-13
JP2008540680A (ja) 2008-11-20
NZ564110A (en) 2010-06-25
US20070053844A1 (en) 2007-03-08
BRPI0609924A2 (pt) 2010-05-11
CN101237853A (zh) 2008-08-06
US20150196589A1 (en) 2015-07-16
EP2402001A1 (en) 2012-01-04
EA016072B1 (ru) 2012-01-30
EA200702520A1 (ru) 2008-06-30
EP1906922A2 (en) 2008-04-09
CN102327285A (zh) 2012-01-25
CA2608752A1 (en) 2006-11-23
NZ593475A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
IL187427A0 (en) Formulations for alteration of biophysical properties of mucosal lining
IL185800A0 (en) Controlled release formulations of octreotide
EP3189859B8 (en) Composition for treatment of cartilage disease
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
IL246026A0 (en) Delayed release of anti-infectives
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
IL186989A0 (en) Therapeutic compositions
EP2001500A4 (en) FORMULATIONS FOR ECALLANTIDE
PL2402005T3 (pl) Formulacje nalbufiny o przedłużonym uwalnianiu
IL197235A0 (en) Therapeutic compositions
IL188448A0 (en) Formulations for enhanced mucosal delivery of pyy
IL190865A0 (en) Formulations of quinolinones
GB2456476A8 (en) Composition for skin or mucosal application
IL193687A0 (en) Formulations of sitaxsentan sodium
IL198760A0 (en) Oral formulations
GB0615108D0 (en) Novel formulations
GB2433117B (en) Histostain composition for an endoscope
GB0521261D0 (en) Prepartaion of bone material
HU0500145D0 (en) Composition for the treatment of oral diseases
EP2024337A4 (en) SOLID DOSAGE FORMULATIONS OF HYDRALAZIN COMPOUNDS
ZA200807682B (en) Novel formulations
ZA200803213B (en) Formulations of quinolinones
GB0720886D0 (en) Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
ZA200800285B (en) Formulations for enhanced mucosal delivery of pyy